Etcembly have been picked by Oliver Sims of Octopus Ventures as one of the top 13 techbio companies to watch.

He says, "As the demand for personalised treatments grows across pharma, Etcembly could have a tool to facilitate the effective development of tailored therapeutic solutions."

Read the full story about top techbio companies here: https://sifted.eu/articles/13-techbio-startups-to-watch-according-to-investors